BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33341940)

  • 1. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
    Chen H; Li M; Ng N; Yu E; Bujarski S; Yin Z; Wen M; Hekmati T; Field D; Wang J; Nassir I; Yu J; Huang J; Daniely D; Wang CS; Xu N; Spektor TM; Berenson JR
    Br J Haematol; 2021 Feb; 192(3):568-576. PubMed ID: 33341940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
    Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
    Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
    Chen H; Li M; Sanchez E; Soof CM; Bujarski S; Ng N; Cao J; Hekmati T; Zahab B; Nosrati JD; Wen M; Wang CS; Tang G; Xu N; Spektor TM; Berenson JR
    Br J Haematol; 2020 Jan; 188(2):283-294. PubMed ID: 31423579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.
    Atanackovic D; Luetkens T; Radhakrishnan S; Kroger N
    Curr Cancer Drug Targets; 2017; 17(9):839-845. PubMed ID: 28875836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
    Deepak HB; Prince SE; Deshpande P
    Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells.
    Noh H; Hu J; Wang X; Xia X; Satelli A; Li S
    Cell Commun Signal; 2015 Feb; 13():14. PubMed ID: 25889536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
    Kearl TJ; Jing W; Gershan JA; Johnson BD
    J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
    Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
    Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
    Rosenblatt J; Avigan D
    Blood; 2017 Jan; 129(3):275-279. PubMed ID: 27919908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
    Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
    Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.
    Vincent-Fabert C; Roland L; Zimber-Strobl U; Feuillard J; Faumont N
    Cell Commun Signal; 2019 Aug; 17(1):89. PubMed ID: 31382969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway.
    Chen D; Tang P; Liu L; Wang F; Xing H; Sun L; Jiang Z
    Cell Cycle; 2018; 17(7):858-867. PubMed ID: 29493401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
    Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
    Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow-derived mesenchymal stem cells inhibit CD8
    Liu Z; Mi F; Han M; Tian M; Deng L; Meng N; Luo J; Fu R
    Clin Exp Immunol; 2021 Jul; 205(1):53-62. PubMed ID: 33735518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
    Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
    Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.